Examining The Role of CGM in T2DM

NACompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

September 30, 2014

Study Completion Date

September 30, 2014

Conditions
DIABETES MELLITUS, NONINSULIN-DEPENDENT, 2 (Disorder)
Interventions
OTHER

Continuous Glucose Monitoring with treatment algorithm

those subjects randomized to Continuous Glucose Monitoring results will be placed in CareLink iPro Clinical Management system, the experimental treatment guideline/algorithm has been programmed into the system. Providers will make treatment decisions based off of results of CGM.

Trial Locations (2)

27599

University of North Carolina, Chapel Hill

30309

Atlanta Diabetes Assoicates, Atlanta

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Medtronic

INDUSTRY

collaborator

Atlanta Diabetes Associates

OTHER

collaborator

UNC Coordinating Center

UNKNOWN

lead

University of North Carolina, Chapel Hill

OTHER

NCT01614262 - Examining The Role of CGM in T2DM | Biotech Hunter | Biotech Hunter